Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke - Way to endeavor

被引:33
|
作者
Huang, Poyin [1 ]
Chen, Chun-Hung [1 ]
Yang, Yuan-Han [1 ]
Lin, Ruey-Tay [1 ]
Lin, Feng-Cheng [1 ]
Liu, Ching-Kuan [1 ]
机构
[1] Kaohsiung Med Univ, Chung Ho Mem Hosp 100, Dept Neurol, Kaohsiung 807, Taiwan
关键词
eligibility; stroke; tissue plasminogen activator; stroke code;
D O I
10.1159/000094994
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The eligibility for recombinant tissue plasminogen activator (rtPA) is rare. We analyze the reasons for exclusion from rtPA among patients who were admitted to our hospital within 3 h. Methods: A strict protocol for hyper-acute stroke was set in a university teaching hospital. Consecutive patients activating the protocol from June 2004 to October 2005 were prospectively registered and entered into a computerized database. The patients were excluded from rtPA according to the modified exclusion criteria from the National Institute of Neurological Disorders and Stroke rtPA trial. Results: Of the 182 patients activating the protocol, only 11 (6.04%) received intravenous rtPA and 4 (2.2%) IA thrombolysis. Patients were excluded for multiple reasons, and the main reasons for exclusion were minor or improving stroke (46.15%), hypertension (35.16%), insufficient time to complete studies or onset beyond 3 h after reconfirmation (24.17%) and intracranial hemorrhage (15.93%). Of 167 excluded patients, 72 (43.11%) were excluded by a single criterion, 53 (31.73%) by 2 criteria and 29 (17.36%) by 3 criteria. The mean time from hospital arrival to presentation to a neurologist was 9.24 +/- 15.11 min (n = 164, median = 8.00, mode = 10, range = 0-65). The mean time from hospital arrival to computed tomography (CT) was 21.67 +/- 23.95 min (n = 167, median = 20.00, mode = 10, range = 4-68). Conclusion: An intrahospital stroke code was implemented to minimize intrahospital delay. However, only 11 patients received intravenous rtPA and 4 IA thrombolysis at our hospital from June 2004 to October 2005. The result brings into question the neurologist's conservative interpretation of the criteria and the necessity to clearly define some criteria. Furthermore an intrahospital stroke code should also be implemented for inpatients to maximize the eligibility for rtPA. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:423 / 428
页数:6
相关论文
共 50 条
  • [41] Efficacy and safety of tirofiban plus recombinant tissue plasminogen activator versus recombinant tissue plasminogen activator alone in acute ischemic stroke patients: a meta-analysis
    Yang, Yonghong
    Yang, Qingwu
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2025, 34 (01):
  • [42] Recombinant desmodus salivary plasminogen activator (desmoteplase) in acute ischemic stroke
    Pugsley, M
    Petersen, KU
    Gupta, S
    Eyding, D
    STROKE, 2006, 37 (02) : 656 - 656
  • [43] THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE ISCHEMIC STROKE - EVALUATION WITH RCBF-SPECT
    HERDERSCHEE, D
    LIMBURG, M
    VANROYEN, EA
    HIJDRA, A
    BULLER, HR
    KOSTER, PA
    ACTA NEUROLOGICA SCANDINAVICA, 1991, 83 (05): : 317 - 322
  • [44] Safety and Effectiveness of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients on Aspirin and Clopidogrel
    Qureshi, Mushtaq H.
    Khan, Shayaan M.
    Jahangir, Nauman
    Malik, Ahmed A.
    Freese, Melissa
    Thompson, Michelle
    Khan, Asif A.
    Suri, M. Fareed K.
    Qureshi, Adnan I.
    STROKE, 2015, 46
  • [45] Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients With Recent Myocardial Infarction.
    Inohara, Taku
    Liang, Li
    Kosinski, Andrzej
    Smith, Eric E.
    Schwamm, Lee H.
    Hernandez, Adrian F.
    Bhatt, Deepak L.
    Fonarow, Gregg C.
    Peterson, Eric D.
    Xian, Ying
    STROKE, 2019, 50
  • [46] Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke
    Laible, Mona
    Jenetzky, Ekkehardt
    Moehlenbruch, Markus
    Ringleb, Peter Arthur
    Rizos, Timolaos
    EUROPEAN NEUROLOGY, 2015, 74 (3-4) : 127 - 134
  • [47] Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke:a dangerous complication
    ZHOU Zhi-gang
    WANG Rui-lan
    YU Kang-long
    中华医学杂志(英文版), 2012, (15) : 2775 - 2776
  • [48] Cost-Effectiveness of Recombinant Tissue Plasminogen Activator in the Management of Acute Ischemic Stroke: A Systematic Review
    Jung, Kee-Taig
    Shin, Dong Wook
    Lee, Kyung-Jin
    Oh, Myungju
    JOURNAL OF CLINICAL NEUROLOGY, 2010, 6 (03): : 117 - 126
  • [49] Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
    Chapman, Sherita N.
    Mehndiratta, Prachi
    Johansen, Michelle C.
    McMurry, Timothy L.
    Johnston, Karen C.
    Southerland, Andrew M.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 75 - 87
  • [50] Recombinant tissue plasminogen activator (rTPA) in young adult patient with acute ischemic stroke: a case report
    Tugasworo, Dodik
    Kurnianto, Aditya
    Retnaningsih, Retnaningsih
    Andhitara, Yovita
    Ardhini, Rahmi
    Dyaksani, Runy
    Budiman, Jethro
    BALI MEDICAL JOURNAL, 2020, 9 (03) : 864 - 868